Compare · VTAK vs WST
VTAK vs WST
Side-by-side comparison of Catheter Precision Inc. (VTAK) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both VTAK and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.19B, about 24453.0x VTAK ($948,208).
- WST has been more active in the news (6 items in the past 4 weeks vs 5 for VTAK).
- WST has more recent analyst coverage (18 ratings vs 0 for VTAK).
- Company
- Catheter Precision Inc.
- West Pharmaceutical Services Inc.
- Price
- $0.26-35.45%
- $328.35-7.74%
- Market cap
- $948,208
- $23.19B
- 1M return
- -77.98%
- -
- 1Y return
- -93.67%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- 2018
- News (4w)
- 5
- 6
- Recent ratings
- 0
- 18
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest VTAK
- Flyte Partners with Blade to Expand Vision Jet Distribution
- Catheter Precision Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form EFFECT filed by Catheter Precision Inc.
- SEC Form 424B3 filed by Catheter Precision Inc.
- Flyte Partners with LifeVac to Equip Every Vision Jet with Life-Saving Equipment
- Flyte Announces Successful Launch of New Direct-to-Consumer Booking Platform
- Creatd Files Form S-1, Reports First Quarter 2026 Results and Updates Annual Meeting Schedule
- Flyte Partners with GSE Worldwide and PGA TOUR Professional Emiliano Grillo, Debuted at the 2026 U.S. Open
- SEC Form S-1 filed by Catheter Precision Inc.
- Volato Closes $2.2 Million PIPE Priced at $0.34 Per Share
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Declares Quarterly Dividend
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target